Advances in biomarkers of biliary tract cancers.
Tumor biomarkers can be applied for early diagnosis or precise treatment, thereby leading to personalized treatment and better outcomes. Biliary tract cancers (BTCs) are a group of cancers that occurs in different locations and have different clinical or genetic properties. Though the incidence of BTCs is rare, BTCs are among the most lethal cancers in the world and all have very low 5-year survivals. Lack of efficient early diagnostic approaches or adjuvant therapies for BTCs are main reasons. These urge us to broaden the researches into BTC biomarkers. Although few progresses of diagnostic biomarkers for BTCs have been achieved, there are still some advances in prognostic, predictive and therapeutic areas. In this review, we will focus on these achievements.
Department of General Surgery, Huashan Hosptial, Fudan University, Shanghai 200040, PR China. Electronic address: 13211220056@fudan.edu.cn.
Jun
J
Hu
Department of General Surgery, Huashan Hosptial, Fudan University, Shanghai 200040, PR China; Department of General Surgery, Jing'an Branch of Huashan Hospital, Fudan University (Jing'an District Centre Hospital of Shanghai), Shanghai 200040, PR China. Electronic address: yinbaobing@126.com.
Baobing
B
Yin
D001661:Biliary Tract Neoplasms / Q000097:blood / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D020928:Mitogen-Activated Protein Kinases
Biliary tract cancer; Biomarker; Cholangiocarcinoma; Gallbladder cancer